Cargando…

Requirements for benefit assessment in Germany and England – overview and comparison

BACKGROUND: This study compared the methodological requirements for early health technology appraisal (HTA) by the Federal Joint Committee/Institute for Quality and Efficiency in Health Care (G-BA/IQWiG; Germany) and the National Institute for Health and Care Excellence (NICE; England). METHODS: The...

Descripción completa

Detalles Bibliográficos
Autor principal:	Ivandic, Victor
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2014
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4884042/ https://www.ncbi.nlm.nih.gov/pubmed/26054401 http://dx.doi.org/10.1186/s13561-014-0012-8

Ejemplares similares

Relevance of indirect comparisons in the German early benefit assessment and in comparison to HTA processes in England, France and Scotland
por: Lebioda, Andrea, et al.
Publicado: (2014)

Benefit assessment in Germany: implications for price discounts
por: Theidel, Ulrike, et al.
Publicado: (2016)

How managed a market? Modes of commissioning in England and Germany
por: Sheaff, Rod, et al.
Publicado: (2013)

Cancer Organizations in France, Belgium, England, Germany and Sweden
por: Spies, John W.
Publicado: (1931)

Childhood and adolescent cancer in Germany – an overview
por: Spix, Claudia, et al.
Publicado: (2023)

Assessing the costs and benefits of perioperative iron deficiency anemia management with ferric carboxymaltose in Germany
por: Froessler, Bernd, et al.
Publicado: (2018)

The historiography of nonconventional medicine in Germany: a concise overview.
por: Jütte, R
Publicado: (1999)

Benefits and risks of benzodiazepines and Z-drugs: comparison of perceptions of GPs and community pharmacists in Germany
por: Hoffmann, Falk
Publicado: (2013)

Perceived parenting and identification with all humanity: Insights from England and Germany
por: Hagel, Minne Luise, et al.
Publicado: (2022)

Patient relevant endpoints in oncology: current issues in the context of early benefit assessment in Germany
por: Dabisch, Inna, et al.
Publicado: (2014)

Patient-reported data informing early benefit assessment of rare diseases in Germany: A systematic review
por: Babac, Ana, et al.
Publicado: (2019)

Assessing the Economic Burden and Benefit-cost of Treating Attention-deficit Hyperactivity Disorder in Germany
por: Kotsopoulos, Nikolaos, et al.
Publicado: (2013)

Initiatives promoting planetary health education in Germany: An overview
por: Schwienhorst-Stich, Eva-Maria, et al.
Publicado: (2023)

How Denmark, England, Estonia, France, Germany, and the USA Pay for Variable, Specialized and Low Volume Care: A Cross-country Comparison of In-patient Payment Systems
por: Quentin, Wilm, et al.
Publicado: (2022)

Critical Overview on the Benefits and Harms of Aspirin
por: Kwok, Chun Shing, et al.
Publicado: (2010)

An Overview to the Health Benefits of Seaweeds Consumption
por: Lomartire, Silvia, et al.
Publicado: (2021)

An overview of adult dental fee exemptions in NHS primary dental care in England
por: Shah, Sagar, et al.
Publicado: (2021)

Comparison of the PATHFAST D-dimer assay with two POC D-dimer assays
por: Spanuth, E, et al.
Publicado: (2015)

Accessibility of general and specialized obstetric care providers in Germany and England: an analysis of location and neonatal outcome
por: Bauer, Jan, et al.
Publicado: (2017)

Partnership trajectories and cardiovascular health in late life of older adults in England and Germany()
por: Djundeva, Maja
Publicado: (2018)

Adaptation planning and the use of climate change projections in local government in England and Germany
por: Lorenz, Susanne, et al.
Publicado: (2016)

Development of trauma systems in Europe—reports from England, Germany, the Netherlands, and Spain
por: Chesser, Tim JS, et al.
Publicado: (2023)

Specialized Staff for the Care of People with Parkinson’s Disease in Germany: An Overview
por: Prell, Tino, et al.
Publicado: (2020)

The impact of additive or substitutive clinical study design on the negotiated reimbursement for oncology pharmaceuticals after early benefit assessment in Germany
por: Dintsios, C. M., et al.
Publicado: (2020)

Specialist mental health services in England in 2014: overview of funding, access and levels of care
por: Docherty, Mary, et al.
Publicado: (2015)

Companies’ Health Technology Assessment Strategies and Practices in Australia, Canada, England, France, Germany, Italy and Spain: An Industry Metrics Study
por: Wang, Ting, et al.
Publicado: (2020)

Requirements for Graduation in Both Medicine and Dentistry in England and Scotland
Publicado: (1886)

Composition of Nuts and Their Potential Health Benefits—An Overview
por: Gonçalves, Berta, et al.
Publicado: (2023)

Early Benefit Assessments in Oncology in Germany: How Can a Clinically Relevant Endpoint Not Be Relevant to Patients?
por: Ruof, Jörg, et al.
Publicado: (2015)

Determination of the target population in early benefit assessments in Germany: challenges for non-small-cell lung cancer
por: ten Thoren, C., et al.
Publicado: (2020)

Septic and Aseptic Operating Theatres for Poor-Law Infirmaries: The Theory and Practice in England and Germany
Publicado: (1913)

A New Practical Formulary of Hospitals of England, Scotland, Ireland, France, Germany, &c.
Publicado: (1836)

Socialisation Influences on Gender Ideologies of Immigrant and Native Youth in Germany, England, Sweden and the Netherlands
por: Sánchez Guerrero, Laia, et al.
Publicado: (2020)

International prevalence of adverse drug events in hospitals: an analysis of routine data from England, Germany, and the USA
por: Stausberg, Jürgen
Publicado: (2014)

Potential cost-effectiveness and benefit-cost ratios of adult pneumococcal vaccination in Germany
por: Kuhlmann, Alexander, et al.
Publicado: (2012)

Overview of digital health teaching courses in medical education in Germany in 2020
por: Aulenkamp, Jana, et al.
Publicado: (2021)

Value and Price of Multi-indication Cancer Drugs in the USA, Germany, France, England, Canada, Australia, and Scotland
por: Michaeli, Daniel Tobias, et al.
Publicado: (2022)

Modelled mortality benefits of multi-cancer early detection screening in England
por: Sasieni, Peter, et al.
Publicado: (2023)

Comparison of post-authorisation measures from regulatory authorities with additional evidence requirements from the HTA body in Germany – are additional data requirements by the Federal Joint Committee justified?
por: Ruof, Jörg, et al.
Publicado: (2016)

Early benefit assessment (EBA) in Germany: analysing decisions 18 months after introducing the new AMNOG legislation
por: Ruof, Jörg, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_v0igsrej4v8iaebe2b3rj2gv57